These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31132584)

  • 21. Rivaroxaban versus high dose nadroparin for thromboprophylaxis after hip or knee arthroplasty.
    Heckmann M; Thermann H; Heckmann F
    Hamostaseologie; 2015; 35(4):358-63. PubMed ID: 26194889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
    Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI
    Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects.
    Moore KT; Byra W; Vaidyanathan S; Natarajan J; Ariyawansa J; Salih H; Turner KC
    Br J Clin Pharmacol; 2015 Jun; 79(6):907-17. PubMed ID: 25475601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
    Spencer RJ; Amerena JV
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Efficacy of Combined Use of Rivaroxaban and Tranexamic Acid on Blood Conservation in Minimally Invasive Total Knee Arthroplasty a Double-Blind Randomized, Controlled Trial.
    Wang JW; Chen B; Lin PC; Yen SH; Huang CC; Kuo FC
    J Arthroplasty; 2017 Mar; 32(3):801-806. PubMed ID: 27663190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and pharmacodynamic evaluation of oral rivaroxaban in healthy adult cats.
    Dixon-Jimenez AC; Brainard BM; Brooks MB; Nie B; Arnold RD; Loper D; Abrams JC; Rapoport GS
    J Vet Emerg Crit Care (San Antonio); 2016 Sep; 26(5):619-29. PubMed ID: 27599304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of Rivaroxaban versus Aspirin for Non-disabling Cerebrovascular Events (TRACE): study protocol for a randomized controlled trial.
    Yang F; Jiang W; Bai Y; Han J; Liu X; Zhang G; Zhao G
    BMC Neurol; 2015 Oct; 15():195. PubMed ID: 26458895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.
    Korjian S; Braunwald E; Daaboul Y; Verheugt F; Bode C; Tendera M; Jain P; Plotnikov A; Burton P; Gibson CM
    Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):186-193. PubMed ID: 29249166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rivaroxaban for post-discharge thromboprophylaxis: the MARINER trial.
    Ramacciotti E; Fareed J
    Int Angiol; 2018 Dec; 37(6):427-430. PubMed ID: 30558402
    [No Abstract]   [Full Text] [Related]  

  • 30. Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study.
    Weitz JI; Bauersachs R; Beyer-Westendorf J; Bounameaux H; Brighton TA; Cohen AT; Davidson BL; Holberg G; Kakkar A; Lensing AW; Prins M; Haskell L; van Bellen B; Verhamme P; Wells PS; Prandoni P;
    Thromb Haemost; 2015 Aug; 114(3):645-50. PubMed ID: 25994838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
    Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
    Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of Late Thromboembolic Complications Post-Fontan Procedure in Relation to Different Antithrombotic Regimens: 30-Years' Follow-up Experience.
    Al-Jazairi AS; Al Alshaykh HA; Di Salvo G; De Vol EB; Alhalees ZY
    Ann Pharmacother; 2019 Aug; 53(8):786-793. PubMed ID: 30788973
    [No Abstract]   [Full Text] [Related]  

  • 33. Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications.
    Kubitza D; Berkowitz SD; Misselwitz F
    Clin Appl Thromb Hemost; 2016 Jul; 22(5):412-22. PubMed ID: 26893445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma D-dimer is not useful in the prediction of deep vein thrombosis after total knee arthroplasty in patients using rivaroxaban for thromboprophylaxis.
    Wu CT; Chen B; Wang JW; Yen SH; Huang CC
    J Orthop Surg Res; 2018 Jul; 13(1):173. PubMed ID: 29996862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism From the Emergency Department (MERCURY PE): Rationale and Design.
    Singer AJ; Xiang J; Kabrhel C; Merli GJ; Pollack C; Tapson VF; Wildgoose P; Peacock WF
    Acad Emerg Med; 2016 Nov; 23(11):1280-1286. PubMed ID: 27537530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
    Coppens M; Weitz JI; Eikelboom JWA
    Circ Res; 2019 Feb; 124(3):416-425. PubMed ID: 30702997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study.
    Haas S; Holberg G; Kreutz R; Lassen MR; Mantovani L; Haupt V; Vogtländer K; Turpie AG
    Vasc Health Risk Manag; 2016; 12():209-18. PubMed ID: 27274266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. The X-PLORER trial.
    Vranckx P; Leebeek FW; Tijssen JG; Koolen J; Stammen F; Herman JP; de Winter RJ; van T Hof AW; Backx B; Lindeboom W; Kim SY; Kirsch B; van Eickels M; Misselwitz F; Verheugt FW
    Thromb Haemost; 2015 Aug; 114(2):258-67. PubMed ID: 25925992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis.
    Lee J; Nakanishi R; Li D; Shaikh K; Shekar C; Osawa K; Nezarat N; Jayawardena E; Blanco M; Chen M; Sieckert M; Nelson E; Billingsley D; Hamal S; Budoff MJ
    Am Heart J; 2018 Dec; 206():127-130. PubMed ID: 30227941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rivaroxaban 2.5 mg. No justification for using this anticoagulant after an acute coronary syndrome.
    Prescrire Int; 2014 Oct; 23(153):229-32. PubMed ID: 25964962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.